Patent Types

    • 2015.03.24

    The method of manufacturing a composite product, containing human adipose-derived multi-potent stem cells, fibroblasts and adipose cells, for skin care or plastic surgery purposes

    This patent concerns the method of manufacturing a composite product containing human adipose-derived adult stem cells, fibroblasts and fat or fat cells, for skin care or plastic surgery purposes.

    • 2015.03.25

    The method of inducing migration of adipose-derived adult stem cells

    This patent pertains to the migration of adipose-derived adult stem cells. To be more specific, it concerns a new usage of adipose-derived adult stem cells, which can migrate to the body areas affected by diseases more effectively following a pretreatment with a specific type of chemokine or a growth factor.

    • 2015.03.24

    Human adipose-derived multi-potent stem cells and the cellular therapeutic agent containing thereof

    This patent pertains to human adipose-derived adult stem cells, which are multi-potent stem cells. To be more specific, it concerns human adipose-derived multi-potent adult stem cells, which can be maintained in its undifferentiated state through the formation of spheres and have an excellent proliferation rate, as well as the method of extracting and maintaining the said adult stem cells, the method of differentiation of the said multi-potent adult stem cells into neurocytes, adipocytes, chondrocytes, osteoblasts and insulin-secreting pancreatic beta cells, and the cellular treatment agents, containing the said adult stem cells or differentiated cells, for breast tissue formation and treatment of osteoarthritis, osteoporosis and diabetes.

    • 2015.03.25

    A composite product containing adipose-derived stem cells for treatment of ischemic diseases of the lower extremities by cell therapy

    This patent pertains to human adipose-derived adult stem cells, which are multi-potent stem cells. To be more specific, it concerns human adipose-derived multi-potent adult stem cells, which can be maintained in its undifferentiated state through the formation of spheres and have an excellent proliferation rate, as well as the method of extracting and maintaining the

    • 2015.03.24

    A cellular therapeutic agent containing human adipose-derived multi-potent stem cells and follicular cells

    This patent pertains to a cellular therapeutic agent, containing human adipose-derived adult stem cells and follicular cells obtained from the scalp tissue, used to induce hair growth. To be more specific, it is regarding a cellular therapeutic agent for hair growth that contains human adipose-derived adult stem cells and scalp hair follicle cells containing CD34-positive and/or negative cells at a designated mixing ratio.
    The cellular therapeutic agent for hair growth obtained according to this patent effectively leads to hair growth when applied in the presence of symptoms that arise in cases where hair follicles do not form properly such as alopecia (hair loss) and atrichia.

    • 2015.03.25

    The method of manufacturing stem cells in a size appropriate for intravascular injections

    This patent concerns the method of manufacturing stem cells in a size, i.e. a diameter of 11 to 16㎛, which is appropriate for intravascular injections. It is also regarding the culture medium used in the manufacture of stem cells in a size appropriate for intravascular injections
    Using this patented method, stem cells can be manufactured in a size that is appropriate for intravascular injections, allowing the stem cells administered into the bloodstream to reach the target tissue area and effectively enhance the effectiveness of activation. Accordingly, it can substantially promote the efficacy of cell therapy in which stem cells are used.

    • 2015.03.25

    Method of preventing disintegration and aggregation of stem cells and the related composite product

    This patent concerns the method of preventing disintegration and aggregation of stem cells. It is also regards the stem cell composite product that is characterized by suspension of stem cells in an aspirin solution and is intravenously administered. In addition, it concerns a composite product for the prevention of disintegration and aggregation of stem cells, which characteristically become suspended in an aspirin solution.

    This patented method can prevent disintegration and aggregation of cells during transport and storage, and effectively, allowing the administered stem cells to reach the target tissue area and effectively enhance the effectiveness of activation. Accordingly, it can substantially promote the efficacy of cell therapy in which stem cells are used.

    • 2015.03.25
    Multi-potency of placenta-derived stem cells

    Multi-potency of placenta-derived stem cells

    This patent concerns placenta-derived multi-potent stem cells and the cellular therapeutic agent containing thereof. To be more specific, amniotic, serous and basal decidua- or placenta-derived tissues are cultured in a culture medium containing bFGF, and they have the following characteristics after the culture process:

    (a) Shows positive immunological responses to CD29, CD44, CD73, CD90 and CD105 and negative immunological responses to CD31, CD34, CD45 and HLA-DR;

    (b) Positive immunological responses are shown in relation to OCT4 and SSEA4;

    (c) The stem cells grow after adhering to plastic and are characterized by round and spindle shapes in terms of morphology. Spheres are formed using FM sphere-forming medium so that the stem cells can be maintained in their undifferentiated state.

    (d) This patent concerns the method of manufacturing placenta-derived stem cells with an ability to differentiate into cells derived from the mesodermal, endodermal and ectodermal cells as well as the placenta-derived stem cells that are acquired.

    The multi-potent stem cells concerned have the ability to differentiate into myocytes, vascular endothelial cells, osteoblasts, neurocytes, astrocytes, adipocytes, chondroblasts or insulin-secreting pancreatic beta cells, and thus can be used to effectively treat osteoporosis, osteoarthritis, neural diseases and diabetes and to form breast tissue.

    • 2015.03.25

    A cellular therapeutic agent containing decidua-derived stem cells for urinary incontinence

    This patent pertains to the cellular therapeutic agent containing decidua- or adipose-derived stem cells for treatment of urinary incontinence. To be more specific, it is regarding the cellular therapeutic agent containing decidua- or adipose-derived stem cells from the placenta or menstrual blood for treatment of urinary incontinence.

    The decidua- or adipose-derived stem cells concerned have the effects of increasing the urinary leak point pressure and improving the contraction power of the urethral sphincter, making them useful as a treatment agent for urinary incontinence.

    • 2015.03.27

    Method of separating, proliferating and differentiating follicular stem cells and the composite product for treatment of baldness

    This patent pertains to human adipose-derived adult stem cells, which are multi-potent stem cells. To be more specific, it concerns human adipose-derived multi-potent adult stem cells, which can be maintained in its undifferentiated state through the formation of spheres and have an excellent proliferation rate, as well as the method of extracting and maintaining the said adult stem cells, the method of differentiation of the said multi-potent adult stem cells into neurocytes, adipocytes, chondrocytes, osteoblasts and insulin-secreting pancreatic beta cells, and the cellular treatment agents, containing the said adult stem cells or differentiated cells, for breast tissue formation and treatment of osteoarthritis, osteoporosis and diabetes.

    The multi-potent stem cells concerned have the ability to differentiate into osteoblasts, neurocytes, astrocytes, adipocytes, chondroblasts or insulin-secreting pancreatic beta cells, despite being adult stem cells, and thus can be used to effectively treat osteoporosis, osteoarthritis, neural diseases and diabetes and to form breast tissue. Also, spheres are formed in a culture medium containing CORM-2 culture so that they can be kept in their undifferentiated state for a long time, and they also have an outstanding proliferation rate, which makes them useful as a cellular therapeutic agent.

    • 2015.03.27

    Method of large-scale proliferation of follicular stem cells

    This patent pertains to the method of proliferating follicular stem cells at a high yield. To be more specific, it relates to the method of acquiring follicular stem cells in a large volume, using specific culture medium to which Rho-associated protein kinase (ROCK) inhibitor is added at a designated concentration level, and the culture medium used in this method.

    The culture medium for follicular stem cells concerned can lead to the proliferation of follicular stem cells, separated from scalp tissue, in an adequate amount for clinical application so that the said follicular stem cells can be used as a cellular therapeutic agent for hair growth to treat alopecia (hair loss) and atrichia.

    • 2015.03.27

    Hair growth promotion agent using autologous follicular cells and its composite product

    This patent concerns the cellular composite product with the function of promoting hair growth using scalp-derived cells with a positive or negative immunological response to CD34. To be more specific, it relates to the cellular composite product for hair growth promotion and hair loss and atrichia treatment agent, containing a certain amount of CD34-positive and –negative cells obtained by culturing the scale tissue outside the body.

    The cellular composite product for hair growth promotion obtained according to this patent is a new type of cellular therapeutic agent that is useful for hair growth promotion.

    • 2015.03.27

    Cellular therapeutic agent containing human adipose-derived multi-potent stem cells and follicular cells

    This patent pertains to the cellular therapeutic agent for inducing hair growth that contains human adipose-derived multi-potent stem cells and follicular cells. To be more specific, it relates to the cellular therapeutic agent for inducing hair growth that contains human adipose-derived adult stem cells and scalp-derived follicular cells containing CD34-positive and/or –positive cells.

    The cellular therapeutic agent for inducing hair growth obtained according to this patent effectively leads to hair growth when applied in the presence of symptoms that arise in cases where hair follicles do not form properly such asalopecia (hair loss) and atrichia.

    • 2015.03.27

    The method of culturing and proliferating hematopoietic stem cells through co-cultivation with adult stem cells

    This patent pertains to the method of culturing and proliferating human hematopoietic and precursor cells. To be more specific, it relates to the method of culturing and proliferating human hematopoietic and precursor cells by separating mononuclear cells from at least one of human peripheral blood, bone marrow or cord blood for a monolayer cultivation process and co-cultivating the monolayer cultured mononuclear cells in the presence of adult stem cells.